RNS Number : 5790E
Medica Group PLC
30 June 2023
 

30 June 2023

 

Medica Group Plc

 

Result of Annual General Meeting

 

 

Medica Group PLC (LSE:MGP, "Medica" or the "Company"), an international provider of high-quality telemedicine services, announces that, at its Annual General Meeting held at 10.30am today at the offices of DLA Piper, 160 Aldersgate Street, London EC1A 4HT, all resolutions put to the meeting were duly passed.

 

Details of the voting are as follows:

 

Resolution

For/

Discretion

(Number of

votes)

%

For/

Discretion

Against

(Number of votes)

%

Against

Total

votes

 

Withheld

(Number of votes)

Ordinary Business

Ordinary Resolutions

1.  

To receive and adopt the annual report, accounts and the auditor's report

66,479,561

100.00

0

0.00

66,479,561

249,911

2.  

To approve the Directors' Remuneration Report

37,121,768

57.83

27,067,040

42.17

64,188,808

2,540,664

3.  

To declare a final dividend

See note below*

4.  

To re-appoint Grant Thornton UK LLP as auditors

66,081,401

99.40

399,054

0.60

66,480,455

249,017

5.  

To authorise the Directors to determine the remuneration of the auditors

66,716,249

99.98

10,759

0.02

66,727,008

2,464

6.  

To re-elect Roy Davis as a Director

65,870,471

99.21

526,381

0.79

66,396,852

332,620

7.  

To re-elect Barbara Moorhouse as a Director

66,204,304

99.22

522,538

0.78

66,726,842

2,630

8.  

To re-elect Joanne Easton as a Director

66,204,415

99.21

524,189

0.79

66,728,604

868

9.  

To re-elect Dr Junaid Bajwa as a Director

65,093,295

97.92

1,384,696

2.08

66,477,991

251,481

10.

To re-elect Stuart Quin as a Director

66,726,029

100.00

813

0.00

66,726,842

2,630

11.

To re-elect Richard Jones as a Director

66,477,880

100.00

111

0.00

66,477,991

251,481

Special Business

Ordinary resolution

12.

General authority to allot shares pursuant to Section 551 Companies Act 2006

66,717,902

99.99

8,940

0.01

66,726,842

2,630

Special resolutions

13.

Standard pre-emption disapplication

64,925,423

97.30

1,800,717

2.70

66,726,140

3,332

14.

Additional pre-emption disapplication for the purpose of financing an acquisition or other capital investment

64,672,763

96.92

2,053,377

3.08

66,726,140

3,332

15.

Authority to make market purchases of up to 12,288,363 shares

65,844,437

99.62

248,149

0.38

66,092,586

636,886

16.          

To authorise general meetings to be held on 14 clear days' notice

66,165,995

99.16

562,609

0.84

66,728,604

868

 

* As previously communicated by an RNS announcement this morning, the resolution to declare a final dividend for the year ended 31 December 2022 of 1.88 pence per share ("2022 Final Dividend") (Resolution 3) was withdrawn prior to, and was not presented to, the AGM. This will ensure shareholders receive 212 pence per share in full without any reduction in respect of the previously proposed 2022 Final Dividend as opposed to two separate payments and in accordance with the terms of the recommended cash acquisition for the Company by Moonlight Bidco Limited (once effected).

 

 

For further information, please contact:

 

Medica Group Plc:

Stuart Quin, Chief Executive Officer

Richard Jones, Chief Financial Officer

 

+44 (0)33 33 111 222

 

FTI Consulting

Victoria Foster Mitchell

Sam Purewal

 

+44 (0)20 3727 1000

Liberum (Joint Broker)

Phil Walker

Richard Lindley

 

+44 (0)20 3100 2000

Numis (Joint Broker)

Freddie Barnfield

Duncan Monteith

Euan Brown

 

+44 (0)20 7260 1000

 

 

About Medica Group PLC

 

Medica (LSE:MGP) is an international provider of high-quality telemedicine services. It is the market leader in teleradiology in the UK and Ireland, working with more than 100 NHS Trusts and HSE hospitals in Ireland, in addition to private hospitals, insurance groups and diagnostic imaging companies. Its network of consultant radiologists, radiographers and specialist doctors interpret and report MRI, CT, ultrasound and X-ray images on behalf of healthcare providers, using Medica's bespoke, secure technology platform for fast and responsive delivery. The company's core services include NightHawk, an urgent, out-of-hours offering available to clients 24/7 with dedicated pathways for stroke and major trauma, and Elective, for routine reporting.

 

In Ireland, Medica carries out patient scanning, as well as reporting, and runs a diabetic retinopathy screening programme for the National Screening Service. Through its US business, RadMD, Medica provides global pharmaceutical and biotech companies, as well as contract research organisations with specialist imaging services for clinical trials.

 

For more information please visit: www.medicagroupplc.com 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGWPURCQUPWGUU